Home » Canada's Drug Listing System Limits Access to New Drugs, Study Says
Canada's Drug Listing System Limits Access to New Drugs, Study Says
January 15, 2007
A new industry-backed study of Canada’s pharmaceutical reimbursement policy and listing recommendations made by four other countries concludes that Canadian patients have “significantly fewer” options when it comes to breakthrough medicines.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor